Virology HIV and Retroviral Replication

Understanding HIV replication is not just a virology exercise; it is the cornerstone of modern HIV medicine, explaining both the relentless progression of untreated infection and the precise mechanism of every life-saving antiretroviral drug. For the pre-med student or MCAT examinee, mastering this cycle provides a framework for immunology, pharmacology, and pathology, connecting molecular events to the clinical reality of acquired immunodeficiency.

HIV Structure and Host Cell Entry

HIV, or Human Immunodeficiency Virus, is a retrovirus, meaning its genetic blueprint is composed of RNA that must be converted into DNA within the host cell. The virus particle is studded with envelope glycoproteins, primarily gp120 and gp41. The critical first step of infection is the highly specific binding of gp120 to a CD4 receptor on the surface of a host immune cell, predominantly helper T-cells, macrophages, and dendritic cells. This initial attachment induces a conformational change in gp120, allowing it to then bind to a coreceptor, either CCR5 or CXCR4. These coreceptors are chemokine receptors normally involved in immune cell signaling. The R5-tropic virus (using CCR5) is typically associated with initial transmission, while X4-tropic variants (using CXCR4) often emerge later and are linked to faster disease progression. Upon coreceptor engagement, gp41 mediates fusion of the viral envelope with the host cell membrane, releasing the viral capsid core into the cytoplasm.

Reverse Transcription: From RNA to Proviral DNA

Once inside the cell, the viral RNA genome is released. This is where the defining retroviral enzyme takes center stage. Reverse transcriptase is an RNA-dependent DNA polymerase that performs the error-prone conversion of single-stranded viral RNA into double-stranded DNA. This process is multi-step: first, the enzyme synthesizes a complementary DNA strand using the viral RNA as a template, creating an RNA-DNA hybrid. The ribonuclease H activity of reverse transcriptase then degrades the original RNA strand. Finally, the polymerase activity uses the remaining DNA strand as a template to synthesize a second, complementary DNA strand, resulting in double-stranded proviral DNA. The high error rate of reverse transcriptase is a key driver of HIV's rapid mutation and evolution, contributing to drug resistance and immune evasion.

Integration and Latency

The newly formed proviral DNA, carried within a pre-integration complex, is transported into the host cell nucleus. Here, another critical viral enzyme, integrase, catalyzes its insertion into the host's chromosomal DNA. Integrase cleaves the host DNA and joins the ends of the proviral DNA to these host chromosome breaks, permanently incorporating the viral genetic instructions. Once integrated, the viral genome is referred to as a provirus. This step is irreversible and establishes a lifelong infection. The provirus may remain transcriptionally silent for a period, creating a state of viral latency. This latent reservoir in long-lived memory T-cells is the major barrier to curing HIV, as these cells are not eliminated by antiretroviral drugs or the immune system and can reactivate to produce new virus later.

Viral Gene Expression, Assembly, and Maturation

When the infected cell is activated, host transcriptional machinery, like RNA polymerase II, transcribes the proviral DNA into new viral mRNA strands. These strands are then exported to the cytoplasm and used as templates for protein synthesis. Initially, viral proteins are produced as long, inactive polyproteins (Gag and Gag-Pol). New viral RNA genomes and these polyproteins assemble at the host cell membrane, where they bud off, acquiring a lipid envelope studded with viral glycoproteins. The immature, non-infectious virion that buds out is not yet functional. Final maturation requires the viral protease enzyme, which cleaves the large polyproteins into their individual, active components (like matrix, capsid, nucleocapsid, reverse transcriptase, and integrase). This processing step causes a dramatic structural rearrangement, creating the mature, infectious virus particle ready to infect a new cell.

Antiretroviral Therapy: Targeting the Replication Cycle

Antiretroviral therapy (ART) uses combinations of drugs that target specific steps in this viral life cycle to suppress replication. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs/NtRTIs) are faulty building blocks that, when incorporated by reverse transcriptase, cause premature termination of the DNA chain. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) bind to a pocket on the reverse transcriptase enzyme, directly inhibiting its polymerase function. Protease Inhibitors (PIs) block the active site of the viral protease, preventing the cleavage of polyproteins and resulting in the release of immature, non-infectious particles. Integrase Strand Transfer Inhibitors (INSTIs) are a cornerstone of modern first-line therapy; they block the integrase enzyme, preventing the proviral DNA from integrating into the host genome. Additional drug classes include Fusion/Entry Inhibitors, which block the initial binding or fusion steps, and Pharmacokinetic Enhancers (like cobicistat), which boost the levels of other drugs. Modern ART typically combines two NRTIs with a third agent from another class (an INSTI, NNRTI, or PI), creating a potent barrier to viral resistance.

Common Pitfalls

1. Confusing Viral Enzymes and Their Targets: A classic MCAT trap is mixing up the functions of reverse transcriptase, integrase, and protease. Remember: Reverse transcriptase works in the cytoplasm to make DNA from RNA. Integrase works in the nucleus to insert that DNA into the host genome. Protease acts after budding to mature the virion.
2. Misunderstanding Coreceptor Usage: Students often think HIV uses CCR5 or CXCR4 from the start. In reality, most transmitted virus is R5-tropic (using CCR5). The switch to X4-tropism (using CXCR4) is a later adaptation that correlates with worsened prognosis, not the initial cause of infection.
3. Overlooking the Significance of Latency: It's easy to focus solely on the active replication cycle. The clinically critical concept is that integrated proviral DNA in a latent state is invisible to ART and the immune system. This reservoir, not the actively replicating virus, is why ART is lifelong and why a true "sterilizing cure" remains elusive.
4. Attributing Immunodeficiency Only to Cell Death: While HIV directly kills infected CD4+ T-cells, the severe immunodeficiency in AIDS arises from multiple mechanisms: direct viral killing, increased apoptosis of uninfected cells, and chronic immune activation that exhausts and dysregulates the entire immune system.

Summary

• HIV is a retrovirus that targets CD4+ immune cells by binding the CD4 receptor and either the CCR5 or CXCR4 coreceptor.
• The viral enzyme reverse transcriptase converts the single-stranded RNA genome into double-stranded DNA, a process prone to errors that drive viral diversity.
• Viral integrase inserts this proviral DNA into the host chromosome, creating a permanent, latent reservoir that is the major obstacle to a cure.
• Following viral gene expression and assembly, the viral protease is essential for cleaving polyproteins into functional parts, producing mature, infectious virions.
• Antiretroviral therapy uses combination drugs targeting these specific steps (e.g., nucleoside analogs for reverse transcriptase, protease inhibitors, integrase inhibitors) to suppress viral replication and prevent the onset of AIDS.